Samsung’s Humira Biosimilar Set For Filings As It Completes Phase III
This article was originally published in PharmAsia News
Executive Summary
The Samsung Group's biopharmaceutical affiliate Samsung Bioepis has successfully completed Phase III global clinical trials for its biosimilar version of Humira, taking another step forward in its ambitions to become a global leader in the development of biosimilars.